Teacher Retirement System of Texas Sells 5,330 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Teacher Retirement System of Texas decreased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 9.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,961 shares of the biotechnology company’s stock after selling 5,330 shares during the period. Teacher Retirement System of Texas’ holdings in BioCryst Pharmaceuticals were worth $397,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 4.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock valued at $14,890,000 after purchasing an additional 91,998 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter worth $192,000. Raymond James Financial Inc. purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter worth $80,000. Swiss National Bank lifted its stake in shares of BioCryst Pharmaceuticals by 6.2% during the 4th quarter. Swiss National Bank now owns 386,568 shares of the biotechnology company’s stock valued at $2,907,000 after buying an additional 22,600 shares in the last quarter. Finally, Cibc World Markets Corp purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at $145,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Up 1.3%

BCRX opened at $8.70 on Friday. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -33.46, a PEG ratio of 1.40 and a beta of 1.04. The stock’s 50-day moving average price is $9.95 and its 200 day moving average price is $8.67. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.02 and a 12-month high of $11.31.

Analysts Set New Price Targets

BCRX has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, June 25th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 28th. Royal Bank Of Canada restated an “outperform” rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Finally, Bank of America upped their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, July 1st. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.70.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.